Australia markets close in 47 minutes

Phathom Pharmaceuticals, Inc. (PHAT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
29.50-0.18 (-0.61%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close29.68
Open29.77
Bid26.00 x 900
Ask30.67 x 1400
Day's range28.92 - 29.79
52-week range26.00 - 50.78
Volume102,123
Avg. volume118,143
Market cap925.017M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-4.54
Earnings date08 Nov 2021 - 12 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est59.67
  • GlobeNewswire

    Phathom Pharmaceuticals to Present New Data at ACG 2021 Annual Scientific Meeting

    FLORHAM PARK, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that data for vonoprazan, an investigational potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related disorders, will be presented at the ACG 2021 Annual Scientific Meeting in Las Veg

  • GlobeNewswire

    Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial

    Vonoprazan met its primary non-inferiority endpoints in both healing and maintenance phasesVonoprazan demonstrated superior healing rates in patients with moderate-to-severe disease at Week 2 versus lansoprazole (PREVACID®), a proton pump inhibitor (PPI)Vonoprazan demonstrated superior maintenance of healing in all patients and patients with moderate-to-severe disease versus lansoprazole at Week 24New Drug Application (NDA) submission planned for H1 2022 targeting the following indications: heal

  • GlobeNewswire

    Phathom Pharmaceuticals Announces Results from VONO-103, a Phase 1 Study Evaluating Gastric Acid Inhibition of Vonoprazan and Lansoprazole (PREVACID®)

    Vonoprazan 20 mg demonstrated significantly greater acid suppressive effects over the 7-day study period compared to lansoprazole (PREVACID®) 30 mg, a proton pump inhibitor (PPI) FLORHAM PARK, N.J., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported results from VONO-103, a Phase 1 trial evaluating the effects of vo